

Daniele Calistri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4820083/publications.pdf>

Version: 2024-02-01

106
papers

2,839
citations

159358

30
h-index

197535

49
g-index

107
all docs

107
docs citations

107
times ranked

5226
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 2195-2202.	3.2	208
2	Free DNA and Carcinoembryonic Antigen Serum Levels: An Important Combination for Diagnosis of Colorectal Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6985-6988.	3.2	115
3	Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>British Journal of Cancer</i> , 2015, 112, 1717-1724.	2.9	112
4	Cell-free DNA as a diagnostic marker for cancer: current insights. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6549-6559.	1.0	104
5	Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 2052.	3.8	99
6	Fecal multiple molecular tests to detect colorectal cancer in stool. <i>Clinical Gastroenterology and Hepatology</i> , 2003, 1, 377-383.	2.4	81
7	Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. <i>Neoplasia</i> , 2017, 19, 637-648.	2.3	81
8	Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. <i>Journal of Cellular Physiology</i> , 2005, 204, 484-488.	2.0	79
9	Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. <i>Clinical Lung Cancer</i> , 2016, 17, 384-390.	1.1	77
10	Microsatellite instability and mutations of p53 and TGF- β RII genes in gastric cancer. <i>Human Genetics</i> , 1996, 98, 601-607.	1.8	75
11	Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1744-1750.	0.8	69
12	Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 37839-37845.	0.8	69
13	GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. <i>Disease Markers</i> , 2016, 2016, 1-6.	0.6	68
14	Multiple-gene panel analysis in a case series of 255 women with hereditary breast and ovarian cancer. <i>Oncotarget</i> , 2017, 8, 47064-47075.	0.8	68
15	p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients. <i>Journal of Cellular Physiology</i> , 2006, 206, 611-615.	2.0	66
16	c-kit and SCF Expression in Normal and Tumor Breast Tissue. <i>Breast Cancer Research and Treatment</i> , 2004, 83, 33-42.	1.1	61
17	Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 307.	1.8	56
18	Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 333-339.	1.4	52

#	ARTICLE	IF	CITATIONS
19	Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study. <i>BioMed Research International</i> , 2013, 2013, 1-5.	0.9	48
20	DNA Methylation profiles as predictors of recurrence in non muscle invasive bladder cancer: an MS-MLPA approach. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 94.	3.5	47
21	Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. <i>Molecular and Clinical Oncology</i> , 2013, 1, 575-581.	0.4	42
22	Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients. <i>Disease Markers</i> , 2015, 2015, 1-6.	0.6	40
23	Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. <i>International Journal of Cancer</i> , 2019, 145, 390-400.	2.3	40
24	The potential use of urine cell free DNA as a marker for cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 1283-1290.	1.5	39
25	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1240.	1.8	38
26	Urine Telomerase: An Important Marker in the Diagnosis of Bladder Cancer. <i>Neoplasia</i> , 2004, 6, 234-239.	2.3	37
27	Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study. <i>Journal of Translational Medicine</i> , 2012, 10, 87.	1.8	37
28	eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. <i>Journal of Translational Medicine</i> , 2015, 13, 258.	1.8	33
29	Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 957.	1.4	32
30	RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. <i>Annals of Oncology</i> , 2006, 17, 424-428.	0.6	31
31	Gene methylation in rectal cancer: Predictive marker of response to chemoradiotherapy?. <i>Journal of Cellular Physiology</i> , 2013, 228, 2343-2349.	2.0	30
32	Cell-free DNA detected by "œliquid biopsy" as a potential prognostic biomarker in early breast cancer. <i>Oncotarget</i> , 2017, 8, 16642-16649.	0.8	29
33	Urine Telomerase Activity for the Detection of Bladder Cancer in Females. <i>Journal of Urology</i> , 2007, 178, 57-61.	0.2	28
34	Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?. <i>International Journal of Molecular Sciences</i> , 2015, 16, 747-757.	1.8	28
35	Telomerase Activity Detected by Quantitative Assay in Bladder Carcinoma and Exfoliated Cells in Urine. <i>Neoplasia</i> , 2001, 3, 446-450.	2.3	25
36	Specific Biomarkers Are Associated with Docetaxel and Gemcitabine-Resistant NSCLC Cell Lines. <i>Translational Oncology</i> , 2012, 5, 461-468.	1.7	25

#	ARTICLE	IF	CITATIONS
37	Contribution of MUTYH Variants to Male Breast Cancer Risk: Results From a Multicenter Study in Italy. <i>Frontiers in Oncology</i> , 2018, 8, 583.	1.3	25
38	Fecal DNA for Noninvasive Diagnosis of Colorectal Cancer in Immunochemical Fecal Occult Blood Testâ€“Positive Individuals. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2647-2654.	1.1	24
39	A possible role of FANCM mutations in male breast cancer susceptibility: Results from a multicenter study in Italy. <i>Breast</i> , 2018, 38, 92-97.	0.9	23
40	Combining cytology, TRAP assay, and FISH analysis for the detection of bladder cancer in symptomatic patients. <i>Annals of Oncology</i> , 2011, 22, 2294-2298.	0.6	22
41	ALKtranslocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA. <i>Cytopathology</i> , 2016, 27, 103-107.	0.4	22
42	Detection of Colorectal Cancer by a Quantitative Fluorescence Determination of DNA Amplification in Stool. <i>Neoplasia</i> , 2004, 6, 536-540.	2.3	21
43	Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study. <i>Radiation Oncology</i> , 2011, 6, 161.	1.2	21
44	miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 2735.	1.0	21
45	Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition. <i>Cancers</i> , 2019, 11, 1340.	1.7	19
46	CDKN1A upregulation and cisplatinâ€“pemetrexed resistance in nonâ€“small cell lung cancer cells. <i>International Journal of Oncology</i> , 2020, 56, 1574-1584.	1.4	19
47	E-cadherin Downregulation and microRNAs in Sporadic Intestinal-Type Gastric Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4452.	1.8	17
48	Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. <i>Journal of Translational Medicine</i> , 2016, 14, 249.	1.8	16
49	Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 65.	3.5	14
50	Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients. <i>Diagnostics</i> , 2020, 10, 269.	1.3	14
51	<i>EGFR</i> and <i>K-ras</i> mutations in cytologic samples from fine-needle aspirates in NSCLC patients: Table 1â€“. <i>European Respiratory Journal</i> , 2012, 40, 267-269.	3.1	13
52	Copy Number Analysis of 24 Oncogenes: MDM4 Identified as a Putative Marker for Low Recurrence Risk in Non Muscle Invasive Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2014, 15, 12458-12468.	1.8	13
53	Cell-Free DNA Integrity Analysis in Urine Samples. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	13
54	Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma. <i>Cells</i> , 2019, 8, 514.	1.8	13

#	ARTICLE	IF	CITATIONS
55	Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	2.9	13
56	Quantitative fluorescence determination of long-fragment DNA in stool as a marker for the early detection of colorectal cancer. <i>Cellular Oncology</i> , 2009, 31, 11-7.	1.9	13
57	Assessment of DNA Damage and Telomerase Activity in Exfoliated Urinary Cells as Sensitive and Noninvasive Biomarkers for Early Diagnosis of Bladder Cancer in Ex-Workers of a Rubber Tyres Industry. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	12
58	First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer. <i>BMC Cancer</i> , 2014, 14, 478.	1.1	12
59	Improved Stool DNA Integrity Method for Early Colorectal Cancer Diagnosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2553-2560.	1.1	12
60	Carcinosarcoma of the prostate: case report with molecular and histological characterization. <i>International Journal of Biological Markers</i> , 2018, 33, 540-544.	0.7	12
61	Genetic and Epigenetic Alterations of CDH1 Regulatory Regions in Hereditary and Sporadic Gastric Cancer. <i>Pharmaceuticals</i> , 2021, 14, 457.	1.7	12
62	Bone metastases detection by circulating biomarkers: OPG and RANK-L. <i>International Journal of Oncology</i> , 2011, 39, 255-61.	1.4	11
63	Molecular determinations of EGFR and EML4-ALK on a single slide of NSCLC tissue. <i>Journal of Clinical Pathology</i> , 2013, 66, 708-710.	1.0	11
64	Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. <i>Drugs</i> , 2015, 75, 1757-1771.	4.9	11
65	The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases. <i>Cancers</i> , 2020, 12, 292.	1.7	11
66	The current role of telomerase in the diagnosis of bladder cancer. <i>Indian Journal of Urology</i> , 2009, 25, 40.	0.2	11
67	Discrepancies between VEGF $\hat{\sim}$ 1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue. <i>International Journal of Molecular Sciences</i> , 2014, 15, 13333-13343.	1.8	10
68	Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience. <i>Biomedicines</i> , 2021, 9, 1299.	1.4	10
69	BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. <i>Oncotarget</i> , 2017, 8, 22640-22648.	0.8	10
70	Development and characterization of a monoclonal antibody directed against human telomerase reverse transcriptase (hTERT). <i>Journal of Biotechnology</i> , 2005, 118, 370-378.	1.9	9
71	Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. <i>International Journal of Biological Markers</i> , 2009, 24, 253-257.	0.7	9
72	PI-PLC $\hat{\sim}$ 21 gene copy number alterations in breast cancer. <i>Oncology Reports</i> , 2012, 27, 403-8.	1.2	9

#	ARTICLE	IF	CITATIONS
73	Urinary biomarkers of non-muscle-invasive bladder cancer: current status and future potential. Expert Review of Anticancer Therapy, 2012, 12, 743-752.	1.1	9
74	Clinical and Genetic Factors Related to Cancer-Induced Bone Pain and Bone Pain Relief. Oncologist, 2014, 19, 1276-1283.	1.9	9
75	Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. International Journal of Biological Markers, 2009, 24, 253-257.	0.7	9
76	Droplet Digital PCR for BCR-ABL1 Monitoring in Diagnostic Routine: Ready to Start?. Cancers, 2021, 13, 5470.	1.7	9
77	Disease family history and modification of breast cancer risk in common BRCA2 variants. Oncology Reports, 2008, 19, 783-6.	1.2	9
78	Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman. Lung Cancer, 2016, 96, 52-55.	0.9	8
79	What influences preneoplastic colorectal lesion recurrence?. Oncotarget, 2017, 8, 12406-12416.	0.8	8
80	Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations. Breast Cancer Research and Treatment, 2008, 112, 343-349.	1.1	7
81	LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation. Oncology Reports, 2012, 28, 2271-2277.	1.2	7
82	Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance. Cancers, 2021, 13, 4515.	1.7	6
83	Digital PCR identifies changes in CDH1 (E-cadherin) transcription pattern in intestinal-type gastric cancer. Oncotarget, 2017, 8, 18811-18820.	0.8	6
84	The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. International Journal of Biological Markers, 2009, 24, 119-129.	0.7	6
85	Impact of Candidate Genetic Polymorphisms in Prostate Cancer: An Overview. Molecular Diagnosis and Therapy, 2016, 20, 1-12.	1.6	5
86	Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 3532.	1.8	5
87	Endometrioid Cancer Associated With Endometriosis: From the Seed and Soil Theory to Clinical Practice. Frontiers in Oncology, 2022, 12, 859510.	1.3	5
88	Detection of germline BRCA1 mutations by Multiple-Dye Cleavase Fragment Length Polymorphism (MD-CFLP) method. British Journal of Cancer, 2001, 85, 845-849.	2.9	4
89	A Comparison of Droplet Digital PCR and RT-qPCR for BCR-ABL1 Monitoring in Chronic Myeloid Leukemia. Blood, 2019, 134, 2092-2092.	0.6	4
90	Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Oncology Reports, 2020, 44, 1561-1573.	1.2	4

#	ARTICLE	IF	CITATIONS
91	EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab. <i>Oncology Letters</i> , 2015, 9, 1432-1438.	0.8	3
92	Serum and Plasma Copy Number Detection Using Real-time PCR. <i>Journal of Visualized Experiments</i> , 2017, , .	0.2	3
93	Evaluation of Colorectal Cancer Risk and Prevalence by Stool DNA Integrity Detection. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	3
94	Rearrangements of ATP5L&KMT2A in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 192, e139-e144.	1.2	3
95	Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR). <i>Journal of Thoracic Disease</i> , 2018, 10, 4858-4864.	0.6	2
96	High grade B-cell lymphoma with <i>MYC</i>, <i>BCL2</i> and/or <i>BCL6</i> rearrangements: unraveling the genetic landscape of a rare aggressive subtype of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1356-1362.	0.6	2
97	Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 2352.	1.7	2
98	Urine Telomerase and Bladder Cancer Detection&”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 998.	3.8	1
99	Population-based screening for hereditary breast cancer in a region of North-Central Italy. <i>International Journal of Molecular Medicine</i> , 2002, 10, 299-305.	1.8	1
100	Case Report: A BRCA2 Mutation Identified Through Next-Generation Sequencing in a Birt&”Hogg&”Dub&” Syndrome Family. <i>Frontiers in Oncology</i> , 2022, 12, 835346.	1.3	1
101	Characterization of Molecular Alterations of BRCA1/2: Analysis and Interpretation Guidelines. <i>Current Women’s Health Reviews</i> , 2012, 8, 4-11.	0.1	0
102	P3.02b-006 Role of TP53 Mutations in Determining Primary Resistance to First-Line Tyrosine Kinase Inhibitors in EGFR-Mutated NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1188-S1189.	0.5	0
103	Right- versus left-side metastatic colorectal cancer: Differences in tumor biology and bevacizumab efficacy. <i>Annals of Oncology</i> , 2017, 28, iii8.	0.6	0
104	Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	0
105	Stool DNA Integrity Method for Colorectal Cancer Detection. <i>Methods in Molecular Biology</i> , 2018, 1765, 193-202.	0.4	0
106	Identification of a novel large EPCAM-MSH2 duplication, concurrently with LOHs in chromosome 20 and X, in a family with Lynch syndrome. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1999-2002.	1.0	0